Lenacapavir Could Prevent 84,000 HIV Infections in Latin America, Access Hindered
Lenacapavir could prevent 84,000 HIV infections in Latin America by 2030, but access is obstructed in Mexico due to high prices and regulatory gaps.
- The Instituto Nacional de Salud Pública (INSP) of Mexico estimates that lenacapavir could prevent 84,000 new HIV infections in Latin America by 2030.
- Despite its potential, access to lenacapavir in Mexico is hindered by private licenses and exorbitant prices, impacting public health efforts against HIV and AIDS.
- Regulatory voids further complicate the distribution of lenacapavir, limiting its availability in Latin America and ultimately impacting the fight against HIV infection.
Por Qué Es Relevante
Access to lenacapavir is critical in combating HIV and AIDS in Latin America, where high infection rates persist. Addressing these access issues could significantly improve public health outcomes across the region.